US FDA lawyers urge no 'do-over' for Avastin breast cancer indication
This article was originally published in Scrip
Unwilling to roll over just yet, Roche unit Genentech made a last-ditch effort to try to save its HER2-negative metastatic breast cancer (MBC) indication for Avastin (bevacizumab), pleading with the US FDA to accept what the firm called its "middle-ground" proposal, which includes a new confirmatory Phase III trial, a risk evaluation and mitigation strategy (REMS) plan and restricting the drug in combination with paclitaxel to only patients with aggressive disease.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.